Having raised a truly phenomenal amount of venture cash over the past five years it appears that Grail might finally be making the leap to the public markets. The liquid biopsy developer has filed to raise $100m in a Nasdaq IPO – a float that will almost certainly see the company bank much more, perhaps in the region of $500m, according to one estimate. The cash will help fund the US launch of Grail’s long-awaited pan-cancer blood test, expected next year. Called Galleri, this is to be sold as an unapproved lab-developed test, to screen asymptomatic people aged over 50 – a setting in which no pan-cancer liquid biopsy is yet available. US approval could follow in 2023, putting Galleri three years behind similar assays from Guardant Health and Roche. A second blood test, in the more familiar setting of diagnosing patients for whom there is a clinical suspicion of cancer could also launch next year. Lastly, a test using blood or tissue is in development to detect residual disease post-treatment. Investors will want these to succeed as soon as possible since Grail is not yet profitable; in the first six months of 2020, Grail made a net loss of more than $136m, a 16% increase year-on-year.
|Grail's VC funding|
|May 2020||Series D||390.0||Canada Pension Plan Investment Board; Existing shareholders; Illumina; PSP Investments; Undisclosed investors|
|Dec 2019||Undisclosed||125.0||Undisclosed investors|
|May 2018||Series C||300.0||6 Dimensions Capital; Ally Bridge Group; Blue Pool Capital; China Merchants Securities; CRF Investment; Hillhouse Capital Group; Huangpu River Capital; ICBC International; Sequoia Capital; Wuxi Nextcode|
|Jan 2018||Series B (second close)||314.7||Undisclosed investors|
|Mar 2017||Series B||900.0||Amazon; Arch Venture Partners; Bristol Myers Squibb; Celgene; Johnson & Johnson Development Corporation; Mckesson Ventures; Merck & Co; Tencent Holdings; Varian|
|Jan 2016||Series A||100.0||Arch Venture Partners; Bezos Expeditions; Bill & Melinda Gates Foundation; Illumina; Sutter Hill Ventures|